Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell in the afternoon session after Truist kept a Hold rating on the shares. The analyst mentioned in a research note that they expected “healthy” Q3 revenue and earnings across the medical technology sector but also braced for “stock volatility.” The note also stated that new money felt notably absent from the space and that there could be excessive reactions to anything counter to crowded positioning. This news came as Integra LifeSciences had previously announced it would release its third-quarter financial results on October 30.

The stock market overreacts to news, and big price drops can present good opportunties to buy high-quality stocks. Is now the time to buy Integra LifeSciences? Access our full analysis report here.

Integra LifeSciences’s shares are extremely volatile and have had 34 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 5 days ago when the stock dropped 5.4% on the news that worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. The president's tone and the suggestion of canceling a meeting with President Xi caused a rapid sell-off in the market. The trade dispute flared up after China imposed export controls on rare earth minerals, which are critical components for high-tech manufacturing. The escalation of the trade war raises concerns about supply chain disruptions and increased costs for technology companies, which are heavily reliant on global trade, leading to a broad sell-off in the sector.

Integra LifeSciences is down 38.4% since the beginning of the year, and at $14.19 per share, it is trading 46.8% below its 52-week high of $26.70 from November 2024. Investors who bought $1,000 worth of Integra LifeSciences’s shares 5 years ago would now be looking at an investment worth $295.96.

Today’s young investors likely haven’t read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.